Cochlear shares jump 6% on guidance upgrade

Demand for Cochlear's products has been stronger than expected in FY 2024.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) shares are on the move on Thursday morning.

At the time of writing, the hearing solutions company's shares are up 6% to $310.00.

Two colleagues at work looking at a tablet and smiling at a rising share price.

Image source: Getty Images

Why are Cochlear shares charging higher?

Investors have been fighting to get hold of the company's shares today after it released an update on its guidance for FY 2024.

According to the release, Cochlear has had a stronger than expected first half for cochlear implant revenue and therefore believes it will now outperform its guidance over the full year.

As a reminder, Cochlear was guiding to underlying net profit of $355 million to $375 million for FY 2024.

However, today's update reveals that it is now guiding to underlying net profit in the range of $385 million to $400 million, which will represent a 26% to 31% increase on FY 2023's result.

First half update

While its results will be released in full later this month on 19 February, management has given investors a taste of what's to come.

It advised that it expects to report a first half sales revenue increase of 25% (20% in constant currency) to $1,113 million with underlying net profit of $192 million.

Cochlear's CEO and President, Dig Howitt, commented:

Cochlear implant trading conditions have been strong across the first half, with units growing 14%. We have maintained the market share gains made in FY23 and market growth has continued to be robust across both developed and emerging markets, as well as all age segments – children, adults and seniors. The key change to our expectations is that we now expect to achieve 10-15% growth in our cochlear implant units for FY24 compared to the high single-digit growth expected in August.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

How does Bell Potter rate these ASX healthcare stocks?

Let's see what the broker is saying about these shares.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Healthcare Shares

Why is this ASX 300 stock rocketing 17% today?

Let's see what is getting investors excited today.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Should you buy CSL and Pro Medicus shares today?

Both stocks have been hammered, but brokers see upside of 60% or more.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech company has piled on more than 25% after a big announcement

A deal around a novel drug delivery compound has investors interested.

Read more »

A young man stands facing the camera and scratching his head with the other hand held upwards wondering if he should buy Whitehaven Coal shares
Healthcare Shares

Telix shares drop despite promising US FDA update

Market weakness is overshadowing this news.

Read more »

Stressed, unhappy and tired scientist with a headache working on a computer in a lab. Worried, anxious and frustrated pathologist, researcher and doctor struggling with burnout, tension and strain.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this ASX share deliver healthy returns or will things get worse?

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »